1.Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
2.Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
3.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, inci-dence, and outcomes. Hepatology 2016;64:73-84.
5.Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
9.Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307.
15.Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-90.
17.Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V. A placebo-controlled trial of subcutane-ous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113-24.
19.Kato H, Nagai Y, Ohta A, Tenjin A, Nakamura Y, Tsuki-yama H. Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. diabetes Res Clin Pract 2015;109:199-205.
21.Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshi-ro N. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014;61:323-8.